Gwen R. Carscadden Sells 10,000 Shares of Intersect ENT Inc (XENT) Stock

Intersect ENT Inc (NASDAQ:XENT) insider Gwen R. Carscadden sold 10,000 shares of Intersect ENT stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $34.35, for a total transaction of $343,500.00. Following the completion of the sale, the insider now owns 13,856 shares of the company’s stock, valued at $475,953.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Intersect ENT Inc (NASDAQ:XENT) opened at $33.95 on Thursday. The stock has a market cap of $1,000.00, a P/E ratio of -54.76 and a beta of 0.67. Intersect ENT Inc has a 12-month low of $11.75 and a 12-month high of $35.34.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.05. The company had revenue of $22.31 million during the quarter, compared to analyst estimates of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The firm’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. equities analysts forecast that Intersect ENT Inc will post -0.63 EPS for the current fiscal year.

A number of analysts have recently commented on XENT shares. Northland Securities reiterated a “hold” rating and issued a $25.00 price target on shares of Intersect ENT in a research note on Friday, November 3rd. BidaskClub lowered shares of Intersect ENT from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. JPMorgan Chase & Co. upgraded shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Zacks Investment Research lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price target on shares of Intersect ENT in a research note on Monday, December 11th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $33.38.

A number of hedge funds and other institutional investors have recently made changes to their positions in XENT. Great West Life Assurance Co. Can bought a new stake in Intersect ENT during the third quarter valued at approximately $116,000. Oppenheimer Asset Management Inc. bought a new stake in Intersect ENT during the third quarter valued at approximately $117,000. Bank of Montreal Can bought a new stake in Intersect ENT during the fourth quarter valued at approximately $135,000. Legal & General Group Plc grew its position in Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the period. Finally, Moors & Cabot Inc. bought a new stake in Intersect ENT during the second quarter valued at approximately $205,000. Institutional investors own 86.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://weekherald.com/2018/01/18/gwen-r-carscadden-sells-10000-shares-of-intersect-ent-inc-xent-stock.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply